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40 It is paramount that any child or adolescent with a suspected difference or disorder of sex development 
41 (DSD) is assessed by an experienced clinician with adequate knowledge about the range of conditions 
42 associated with DSD and is discussed with the regional DSD service. In most cases, the paediatric 
43 endocrinologist within this service acts as the first point of contact but involvement of the regional 
44 multidisciplinary service will also ensure prompt access to specialist psychology and nursing care. The 
45 underlying pathophysiology of DSD and the process of delineating this should be discussed with the 
46 parents and affected young person with all diagnostic tests undertaken in a timely fashion. Finally, for rare 
47 conditions such as these, it is imperative that clinical experience is shared through national and 
48 international clinical and research collaborations. 
49
50 Introduction & development of guidance
51 Differences or disorders of sex development (DSD) are a wide range of conditions with diverse features 
52 and pathophysiology (1) that most often present in the newborn or the adolescent. Newborns with DSD 
53 usually present with atypical genitalia whereas adolescents present with atypical sexual development and 
54 maturation during the pubertal years. These clinical situations can often be challenging to evaluate as they 
55 can present in a wide range of paediatric and adult settings. Developing a logical and pragmatic 
56 management plan for investigations whilst establishing a dialogue and building rapport with the child or 
57 adolescent and the parents are central to the initial approach and ongoing management. 
58
59 The consensus reached in 2005 on the general principles of managing patients with DSD represented a 
60 historic milestone for international collaboration in this area (2). Over the last two decades, and as a direct 
61 result of the above initiative, multidisciplinary and international collaborative projects such as EuroDSD, I-
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63 generate new knowledge and guidance (3). Since guidance on the initial evaluation of a complex condition 
64 is often influenced by local provision of health care, it was felt that reaching a consensus at a national level 
65 was the most effective means of improving care in the UK. A UK DSD taskforce was initially formed in 
66 2009 under the auspices of the UK Society for Endocrinology with the remit of formulating guidance on 
67 the initial evaluation process and the diagnostic approach (4). After completion, the document was subject 
68 to open external review by the involved professional societies, patient group representatives and wider open 
69 consultation. The guidance was subsequently revised and re-published in 2015 (5). The current, second, 
70 revision of the guidance was initiated in 2020 and has also taken a similar path as described above. The 
71 main focus of this guidance has remained on the initial approach to the care of the infant or adolescent who 
72 presents with a suspected DSD.
73
74 The multidisciplinary team 
75 Optimal care for infants and adolescents with DSD requires an experienced multidisciplinary team (MDT) 
76 that is accessible through regional centres or clinical networks that link between one or more specialist 
77 centres. It is clear that many centres that deliver care in DSD do not have access to the whole range of 
78 expertise that may be required (6,7). As a minimum standard, the clinical team for children should include 
79 specialists in paediatric endocrinology, paediatric urology, paediatric clinical psychology, paediatric 
80 radiology, paediatric nursing and, in the case of newborn infants, neonatology and, in the case of the older 
81 child, an adolescent gynaecologist.  All patients should also have a named keyworker which could be the 
82 specialist nurse in the team, but the family and young person should also be able to directly contact the lead 
83 clinician. In addition, the core MDT should have links to a wider MDT which includes specialists from 
84 clinical genetics, clinical biochemistry, adult endocrinology, adult urology, assisted conception, plastic 
85 surgery, gynaecology, adult clinical psychology, psychiatry, social services, sex therapy and if possible a 
86 clinical ethics forum  (Table I).  The parents and the young person should be informed of the range of 
87 support that is available. The MDT has a responsibility to learn and develop their practice and that of other 
88 services in their network and region including non-specialists who are often the first point of contact in a 
89 new presentation. The network should have a forum to meet regularly, in the context of a clinic or an 
90 educational meeting where the team can review and discuss its own performance. Members of the MDT 
91 should also be aware of how their own values and beliefs are played out in the clinical setting. Engagement 
92 of the MDT in quality improvement exercises as well as in building collaborative working partnerships, 
93 attendance at joint clinics and education events are crucial if knowledge and information sharing as well as 
94 care is to be optimised within the team. The role of a service manager or a clinic coordinator as well as a 
95 database administrator has not been sufficiently emphasized in the past. Whilst, it is possible that some of 
96 these roles can be assumed by one of the existing members of the MDT, there is still a need for dedicated 
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98 service. For certain rare conditions associated with DSD, the need for an out of region referral or discussion 
99 may be required. Virtual electronic platforms, such as the clinical patient management system (CPMS) that 
100 is available to centres affiliated to the European Reference Network (ERN) for rare endocrine conditions 
101 (Endo-ERN) can provide a forum where a complex case can be remotely and securely discussed with 
102 several experts at short notice (8). The use of secure NHS-approved web-based platforms may also obviate 
103 the need for immediate physical transfer of a patient or a family for specialist MDT input.
104
105 Networks & registers for clinical care, audit & research 
106 It is unrealistic to expect that every clinical centre can possess a comprehensive, multidisciplinary DSD 
107 team as outlined above. Furthermore, in many cases, care at a local hospital with early telephone or secure 
108 video-link consultation with the regional centre may be more appropriate for reasons of both convenience 
109 and necessity (for example, adrenal crisis in CAH). For the less complex case of hypospadias, immediate 
110 multidisciplinary input may not be necessary and initial discussion and explanation of the condition with 
111 the parents does not require urgent transfer of the baby at an emotionally sensitive period. Similarly, some 
112 investigations can also be performed at local centres that are affiliated to a regional centre. However, all 
113 centres managing children and young people with DSD should have a specialist multi-disciplinary DSD 
114 team that can be accessed by its regional network and as described earlier. It is also important that all 
115 personnel who may be involved in the care of an affected person have access to the regional DSD team and 
116 have the opportunity to develop themselves professionally. Recent international surveys show that 
117 engagement in research and quality care improvement as well as participation in registries and continuous 
118 professional development activities is variable amongst centres that deliver DSD care (6).  Some regions in 
119 the UK, such as Scotland, have attempted to overcome these hurdles with the development of a managed 
120 clinical network (91). A service model such as this is aimed at ensuring the provision of a high quality and 
121 equitable service for all affected children and adolescents in a region. A formal organisation such as this 
122 has the potential to develop a structured referral pathway within the region as well as beyond and can 
123 provide the infrastructure for better long-term care of the patient as close to home as possible. In England, 
124 DSD care is considered a ‘specialised service’ directly commissioned by NHS England but, currently, no 
125 formalised national network exists.
126
127 In addition to ‘getting it right the first time’, networks can have several other benefits in the field of DSD. 
128 A network can facilitate the creation of widely agreed protocols for the care of the affected newborn, set 
129 and monitor national standards of care, inform the rational utilisation of other services such as clinical 
130 genetics and clinical biochemistry and provide a forum for education and professional development. More 
131 recently, European networks, such as Endo-ERN and a urology network (eUROGEN) of reference centres 
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133 as the Scottish DSD network and Endo-ERN have ongoing surveillance capability through projects such as 
134 the Scottish Audit of Atypical Genitalia (SAAG) (9) and EuRRECa (10) that allow continuous monitoring 
135 of clinical activity. Professional scientific societies also play an important role and many such as the 
136 BSPED and ESPE have a dedicated special interest group for DSD. Under the aegis of the BSPED, the 
137 BSPED DSD working group has developed auditable standards of care (11). 
138
139 Research and audit are vital for the management of DSD and clinical networks have a strong potential to 
140 drive these activities with the development of care standards including patient experience data and peer-
141 observation of clinical care provision. Following the 2005 Consensus Workshop that stressed the need for 
142 the regular collection and sharing of data across geographical boundaries, the current I-DSD registry was 
143 initially launched in 2008 (12). Over a decade later, this registry and its associated network, I-DSD play an 
144 increasingly important role in supporting research, training and benchmarking of care and service (13).  
145 Patient registries can also facilitate the development of local circles of patients and parents with similar 
146 conditions who can support each other. The case for participating in standardized data collection and 
147 exchange for DSD has now been made at several levels and should be standard practice in centres that care 
148 for people with DSD (2, 3, 11, 14, 15).  
149
150 Communication
151 Ideally, discussions with the family are led by one professional. In most situations, particularly in the case 
152 of the newborn, the paediatric endocrinologist assumes the role of clinical lead and oversees the timely 
153 involvement of other members of the team. Other team members should be discouraged from providing 
154 results as soon as they are received. For infants, this team should develop a plan for clinical management 
155 with respect to diagnosis, sex assignment, management choices band psychosocial care. The lead clinician 
156 should process this information and take responsibility for sharing the information with the team and the 
157 parents so that informed decisions can be reached in a timely manner (16). The process of informing 
158 parents, children and young people of the various investigations and results should be discussed and 
159 documented such that the whole MDT team is aware of the status of new or ongoing conversations with the 
160 family. Ongoing communication with the family’s general practitioner is important and consent for sharing 
161 information should be discussed with parents and young person. The patient and family should also be 
162 provided details of resources that can provide peer support that is independent of the clinical service. A 
163 record of early discussions, either as audio recordings or a letter, which is shared between the parents and 
164 other immediate members of the MDT and the general practitioner are helpful for all. The decision-making 
165 history that is captured in these records can be especially important for parents who can then revisit the 
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167 translation services to ensure the letter is accessible to the patient or parents. Use of drawings and written 
168 material during discussion as well as information sheets are also useful aids for families.
169
170 Discussions with parents and young people need to occur on multiple occasions in a quiet and peaceful 
171 setting, with enough time for the family and MDT to develop a shared understanding of investigations, 
172 results, diagnosis, management and the value of ongoing psychological care for both themselves and/or 
173 their child. The pace at which information is shared should be set by the family, and issues of 
174 confidentiality should be discussed and respected (17).  Parents’ and young people’s initial recollections of 
175 conversations with professionals may have long-lasting effects on them and their relationship with their 
176 child and health professionals and, therefore, MDT training is required in the use of appropriate language 
177 that can contribute to psychologically appropriate care and avoid unnecessary harm (18). The use of 
178 phrases such as ‘diverse’ or ‘variations’ in sex development may help to introduce the concept of the range 
179 of variation that may occur in typical sex development. Some peer information and support organisations 
180 prefer terms such as ‘intersex’ or ‘variations in sex characteristics’. The young person and their family may 
181 adopt terms that best suit their psychosocial position and these choices need to be respected. The team 
182 should be cognizant of the needs of the parents who do not use English as their first language. It is also 
183 possible that for rare dialects and languages, the interpreter may originate from the same community. 
184
185 From the outset, parents and young people need to be aware that the management of the condition will 
186 require a stepwise approach that first targets short-term goals without compromising more distant goals that 
187 together achieve optimal long-term well-being (19). Families’ contributions to decisions on care will be 
188 shaped by their own expectations, experiences, and their understanding of sex and gender roles within the 
189 religious and cultural context of their own social networks. The complexity of the psychological and 
190 physical impact of intervention genital difference will require a thorough discussion with several members 
191 of the MDT so that the parents are fully informed and can understand the care plan to which they are asked 
192 to consent (20, 21). In cases where a high value is placed on religious opinions, centres may choose to 
193 involve an experienced religious leader such as a hospital chaplain, imam or rabbi to provide help and 
194 understanding when addressing the patient’s or parents’ concerns. The parents and young people may need 
195 support and guidance as to how to share essential understanding within their close community and those in 
196 trusted caring relationships with the child in a way that both utilises existing support whilst preserving the 
197 child’s need for privacy, dignity and self autonomy (22, 23). In addition, adolescents will need direct 
198 support in navigating complex issues such as the potential for any intervention before embarking on sexual 
199 activity, decisions regarding gonadectomy, medication management and the potential for fertility 
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202 Psychological care 
203 When a child or young person is identified for investigation regarding a possible DSD, immediate 
204 psychological care for patient and family should be provided by the whole team and led by the clinical 
205 psychologist. The initial aim is to orientate the family to the psychological tasks and practical demands 
206 ahead. There is good evidence in a wide range of chronic childhood conditions that the early involvement 
207 of the psychologist can be helpful and information giving combined with psychological techniques 
208 focussed on parents’ thinking can help with parental adaptation (24). While there is a need to study these 
209 interventions in more detail within the field of DSD, early provision of psychosocial support is increasingly 
210 becoming standard practice in the newborn period (25) and it should also be considered good practice in the 
211 setting of DSD.  Decision making processes and tools have been suggested as useful methods of engaging 
212 parents in a way that provides information and is supportive (22). Such psychosocial support will allow 
213 those impacted to examine and understand their early emotional reactions as well as explore present and 
214 future worries, adjust to the period of uncertainty during the initial diagnosis process and prepare for 
215 ongoing engagement with healthcare, whilst facilitating inclusion in informed decision making about 
216 themselves or their child (26). The clinical psychologist is also well placed to assess the level of care the 
217 family needs, assess and facilitate the bonding of the parents with the newborn, and, in the case of the 
218 young person, perform an assessment of gender identity, when appropriate. The psychological care that is 
219 provided as part of the initial approach should always be considered as a routine part of the care that is 
220 available and offered to the child or the parent. Although parents of all infants with atypical genitalia may 
221 need psychological care (27), as a minimum, the parents of every newborn with suspected DSD where there 
222 has been a delay in sex assignment should be provided immediate clinical psychology input. An approach 
223 which is more appropriate for an adolescent needs to be adopted in the case of a new diagnosis in this age 
224 group (28). All adolescents with a newly diagnosed DSD or existing DSD requiring medical or surgical 
225 attention should also receive clinical psychology input in addition to any support provided to their parents 
226 or wider family. A standardised assessment of the need for future clinical psychology input should also 
227 become routine at the point of transfer from paediatric to adult services. In the MDT, the clinical 
228 psychologist has important additional roles that include the training of team members in communication 
229 and provision of input into tools that are used to collect patient/parent reported experience of the care 
230 received.
231
232 The role of peer support and advocacy groups
233 Based on lived experiences across the life span, peer groups can provide ongoing support to parents and the 
234 affected individual, including opportunities to gather and explore practical information, promote autonomy, 
235 and build knowledge and self-confidence regarding the diagnosis of DSD (29). For parents, gathering, 
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237 child or young person and therefore need to be fully informed about DSD practice, short and long term 
238 outcomes of treatments and health risks and psychological challenges for their child. By being in touch 
239 with others with a similar condition and engaging with a peer group, people can gain a sense of 
240 empowerment and the whole experience may also normalise a condition which may have previously been 
241 perceived as a source of stigma. Peer groups can provide a range of such information via websites and 
242 newsletters as well as via telephone and online forums and group meetings for both families and 
243 professionals (30).  Contact details of national peer groups and web resources such as CAH Support Group 
244 (livingwithcah.com) and dsdfamiles (dsdfamilies.org) should be supplied as routine as part of any written 
245 information. Whilst such groups and resources are not subject to a standard process of national 
246 accreditation in the UK, the co-involvement of local clinical experts as advisors means that many groups 
247 function within the framework of clinical practice in the UK. It is possible that families or individuals may 
248 prefer to talk to others known to the MDT or regional services. The creation of a local pool of support 
249 volunteers, contributing to education and support events is a valuable adjunct to a regional service. A 
250 patient’s interest in peer contact may change over time and therefore this should be reviewed intermittently 
251 by the MDT. Peer support groups as well as patients can also work in partnership with health care providers 
252 at several levels in improving the quality of care and research (30). For instance, through international 
253 projects such as DSDnet, I-DSD, I-CAH and, more recently Endo-ERN,  patients and peer groups have 
254 been able to provide guidance on health care and research (14).
255
256 Which newborn should be investigated?
257 It is generally accepted that investigations are necessary in those cases where the appearance of the 
258 genitalia is such that sex assignment is not possible at birth or the appearance is not consistent with any 
259 prenatal genetic tests. However, the interpretation of the genital appearance and the ability to assign sex in 
260 some cases may depend on the expertise of the observer. Whilst the label of ‘ambiguous genitalia’ has often 
261 been assigned to newborns in whom the most appropriate sex of rearing is not immediately clear to those 
262 present at the child’s birth, in most cases, the genitalia are not ‘ambiguous’ but simply ‘atypical’ and we 
263 recommend that the term ‘atypical’ should be used instead of ‘ambiguous’. The birth prevalence of atypical 
264 genitalia may be as high as 1 in 300 births (31) but the birth prevalence of infants who require specialist 
265 input in the neonatal period is about 1 in 3,000 and the birth prevalence of infants  in whom sex assignment 
266 is delayed beyond birth may be as low as 1 in 11,000 births (8). 
267
268 When evaluating infants, the clinical features of the external genitalia that require examination include the 
269 presence of gonads in the labioscrotal folds, the fusion of the labioscrotal folds, the size of the phallus and 
270 the site of the urinary meatus on the phallus, although the real site of the urinary meatus may, sometimes, 
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272 aggregate score, the external masculinisation score (EMS) (33). More recently, the external genitalia score 
273 (EGS), has been developed as a gender-neutral alternative to the EMS (34). The EGS describes the site of 
274 urethral meatus and genital tubercle length in greater detail but continues to have a high level of correlation 
275 to the original EMS tool (34). In boys with atypical genitalia, a chromosomal anomaly may be present in 
276 approximately 3% of those with isolated cryptorchidism, 7% of those with hypospadias and 13% of those 
277 with a combination of cryptorchidism and hypospadias (35).  In boys with XY DSD, comprehensive 
278 investigations will reveal an endocrine or genetic abnormality in at least a quarter of cases (36-39). Routine 
279 systematic examination of 423 consecutive, apparently healthy, term newborn boys revealed that 412 
280 (98%) had the maximum EMS of 12, 10 had an EMS of 11 and only 1 out of 423 had an EMS of less than 
281 11 (33). Thus, infants who require further clinical evaluation and need to be considered for investigation for 
282 a suspected DSD should include those with isolated perineal hypospadias, isolated micropenis, isolated 
283 clitoromegaly, any form of familial hypospadias, isolated bilateral undescended testes and those who have 
284 an EMS of less than 11 or an EGS of less than 10.5 (33,34). This will avoid unnecessary detailed 
285 investigations of boys with isolated glandular or mid-shaft hypospadias and boys with unilateral inguinal 
286 testis. In newborn girls, the length of the clitoris does not seem to be dependent on gestation and a newborn 
287 with a length greater than 8mm requires further evaluation (40). Micropenis is defined as a stretched penile 
288 length of less than 2.5SD from the mean and based on contemporary studies from a wide range of 
289 countries, a stretched penile length of less than 2cm would represent a reasonable cut off for micropenis in 
290 the newborn (34, 41-45). In approximately 25% of affected cases, XY DSD is part of a complex multi-
291 system condition (37, 46) and the coexistence of a systemic metabolic disorder, other associated conditions 
292 or dysmorphic features would lower the threshold for investigation as would a family history of 
293 consanguinity, stillbirths, multiple miscarriages, fertility problems, genital abnormalities, hernias, delayed 
294 puberty, genital surgery, unexplained deaths and the need for steroid replacement. Knowledge of birth 
295 weight in XY DSD is very helpful given the well reported association between low birth weight, intra-
296 uterine growth retardation and XY DSD (31, 47). 
297
298 What investigations should be performed?
299 In all infants with atypical genitalia and/or bilateral impalpable gonads, a first tier of investigations should 
300 be undertaken to define the sex chromosomes and delineate, by pelvic ultrasound, the internal genitalia and 
301 exclude congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency – the commonest cause of 
302 a life-threatening condition that is associated with atypical genitalia in the newborn. This first tier should, 
303 therefore, also include plasma glucose, serum 17OH-progesterone (17OHP), and serial measurement of 
304 electrolytes. Serum 17OHP is usually unreliable before the age of 36 hrs, and in the salt losing form of 
305 CAH, serum electrolytes usually do not become abnormal before day 4 of life. Furthermore, 17OHP 
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307 forms of CAH. The results of PCR or FISH analysis using Y and X-specific markers and the 17OHP results 
308 should be available within a maximum of two working days in all specialist centres. In situations where the 
309 level of suspicion of CAH is very high and the infant needs immediate steroid hormone replacement 
310 therapy, further serum and urine samples should be collected and stored before starting therapy. These 
311 should be of a sufficient volume to assess 17OHP, testosterone, androstenedione, renin activity and 
312 aldosterone, in that order of priority.  Baseline or stimulated serum cortisol concentrations can be difficult 
313 to interpret in the newborn especially in the premature infant or following prenatal or postnatal exposure to 
314 glucocorticoids. At least one spot or 24-hour urine sample (at least 5ml) for a urine steroid profile (USP) 
315 should be collected before starting therapy. The results of these initial investigations, and especially the 
316 karyotype, shall often dictate the second tier of investigations. It is imperative that a regional protocol that 
317 is easily available within the region by all health care staff has been developed for these first-tier 
318 investigations and this protocol should include details of sample collection and transport as well as contact 
319 details of key staff (48).  
320
321 In an infant with atypical genitalia, impalpable gonads and a karyotype of 46, XX, and the presence of a 
322 uterus, the diagnosis of CAH due to 21-hydroxylase deficiency is very likely. A significantly elevated 
323 serum 17OHP as well as a wider range of androgens and a urine steroid profile can confirm this diagnosis 
324 and can also identify other rare forms of CAH such as 11hydroxylase deficiency. In other infants who 
325 are not 46, XX and have had CAH excluded, it is necessary to determine the presence of testes as well as 
326 the adequacy of androgen production and at the initial stage this will include the measurement of 
327 gonadotrophins, testosterone, serum anti-Müllerian hormone (AMH) and/or serum inhibin B as well as 
328 further detailed imaging and laparoscopy. A urine sample should also be collected to assess proteinuria. 
329 However, the onset of proteinuria in the glomerulopathy associated with WT1 variants is very variable and 
330 if there is a high suspicion then there may be a need for repeated assessments (49).
331
332 Which adolescent should be investigated and how extensively?
333 The initial assessment in an affected adolescent should not only start the process of diagnosis but should 
334 also be used to develop a rapport with the patient and where appropriate, their parents. The delivery of 
335 medical, nursing and psychological care needs to be undertaken within a hospital setting that is sensitive for 
336 the needs of the young person. The explanation of the diagnosis to the patient and the family is critical and 
337 needs to be performed sensitively and carefully over a period of time for reflection and this can be 
338 facilitated via expert psychological input. Adolescents usually present to paediatric or adult health care 
339 teams with a suspected DSD in three ways - a girl with primary amenorrhea (with or without breast 
340 development), a girl who virilises at puberty or a boy with pubertal delay (Fig.1). The need for any physical 









This article is protected by copyright. All rights reserved
342 health professionals within the MDT and with the help of the psychologist or specialist nurse, if necessary. 
343 Any examination in clinic should be deferred to subsequent consultations once a rapport has developed 
344 with the adolescent.  In some cases, this may be best performed under an anaesthetic by a surgeon and/or a 
345 gynaecologist. In adolescents with an existing DSD, the period of transition to adult services is an 
346 opportunity to review the diagnosis and consider further investigations. The joint DSD clinic serves as the 
347 forum where this can be reviewed. This clinic can also function as the forum where new cases in older 
348 adults can be discussed within the wider MDT.
349
350 In girls with primary amenorrhoea, investigations should be considered at the age of 13 years if there is no 
351 breast development and by 15 years if other aspects of puberty, particularly breast development, have 
352 progressed normally. History should include a family history and an assessment of coexisting chronic 
353 disease, exercise and weight changes. Physical examination should include measurement of blood pressure, 
354 height and weight and assessment of secondary sexual characteristics including clitoral enlargement. 
355 Vaginal examination to assess vaginal length is only indicated when considering vaginal dilation as it is not 
356 of diagnostic value alone and should be performed by a gynaecologist. The procedure is only required 
357 when the individual wishes or when sexual activity is contemplated. An initial investigation screen should 
358 combine a transabdominal pelvic ultrasound to identify a uterus with measurements of serum electrolytes, 
359 LH, FSH, prolactin, TSH, FT4, SHBG, androstenedione, oestradiol, testosterone, AMH or Inhibin B. 
360 Ultrasound scans do not yield information on vaginal anatomy and this is better obtained from magnetic 
361 resonance imaging (MRI), which is most useful in cases where there is menstrual obstruction. Raised 
362 gonadotrophins or an absent uterus in the presence of normal breast development necessitate chromosome 
363 analysis (by karyotype or microarray). 
364
365 The appearance of clitoromegaly and hirsutism at puberty in the presence of primary amenorrhoea is a 
366 classical presentation of 17β-hydroxysteroid dehydrogenase type 3 deficiency and 5-reductase type 2 
367 deficiency and can also be seen in SF-1 deficiency (50). It is less typical of partial androgen insensitivity 
368 syndrome (PAIS) which is usually associated with atypical genitalia at birth. In all these conditions, 
369 Müllerian structures will not be detectable. Also, in partial gonadal dysgenesis and ovotesticular DSD, the 
370 mild clitoromegaly that may have been present at birth but overlooked, may become a more prominent 
371 feature at adolescence (50). The differential diagnosis would also include 46, XX CAH and androgen-
372 secreting tumours of the ovary or adrenal gland; in all these cases Müllerian structures are present. 
373 Investigations include serum measurements of LH, FSH, DHEAS, SHBG, androstenedione, testosterone, 
374 dihydrotestosterone and 17OHP. A USP can confirm a diagnosis of 5-reductase type 2 deficiency, 
375 disorders of androgen excess or adrenocortical tumour.  A pelvic ultrasound will assess the presence of a 
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377
378 Although the commonest cause of delayed puberty is constitutional delay, all boys with delayed puberty 
379 who are over the age of 14 years should be assessed carefully (51). Boys who are overweight or who have 
380 penoscrotal webbing need careful examination so that a normal penis is not mistaken for micropenis. 
381 Rarely, PAIS, a disorder of testosterone biosynthesis or mild forms of testicular dysgenesis can present in 
382 this age group, especially if there is a history of hypospadias repair, orchidopexy or gynaecomastia. First 
383 line investigations include a bone age and serum measurements of LH, FSH and testosterone. For those 
384 with raised gonadotrophins, chromosome analysis should be performed to exclude conditions such as 
385 Klinefelter’s syndrome (47, XXY and mosaic variants) or 45, X/46, XY mosaicism.
386   
387 The role of the clinical geneticist 
388 Establishing a specific molecular diagnosis is helpful in the clinical management of cases and in offering 
389 accurate genetic counselling for the family. In those cases, where a clear steroidogenic defect has been 
390 identified biochemically, targeted single gene analysis will confirm the diagnosis in most cases. Whilst the 
391 yield from diagnostic genetic testing maybe less than 50% in those who are 46, XY DSD and have no clear 
392 abnormality of steroidogenesis, with ongoing advances in genomic medicine (52), the ability to better 
393 diagnose, predict and treat disease is anticipated to transform many aspects of care. For a significant 
394 number of individuals with a DSD, its utility may reside in ending diagnostic uncertainty and delivering 
395 personalised care. 
396
397 Diagnostic genetic laboratories are moving from single gene sequencing to high-throughput sequencing 
398 (HTS) assays (parallel testing), designed to sequence multiple DSD-related genes on a targeted panel in one 
399 analysis or through whole genome or exome sequencing (WGES) with predetermined filters that target 
400 DSD-related genes (6, 53). A targeted panel is advantageous as it yields high-quality coverage of the genes 
401 of interest, whilst minimizing the risk of incidental findings. Recent surveys of practice show the increasing 
402 use of HTS at an earlier stage of the diagnostic pathway in XY DSD (6) and with greater familiarity with 
403 this approach, as well as faster turnaround times, it is clear that practice is changing, such that, the choice of 
404 second-line endocrine investigations may be influenced by the results of the genetic analysis (54).  
405
406 The clinical geneticist at the specialist DSD centre can evaluate complex genetic syndromes and advise 
407 which genetic testing technique is appropriate and cost-effective for each clinical situation, following 
408 urgent confirmation of chromosomal sex. Initial testing is usually performed by quantitative fluorescence 
409 polymerase chain reaction (QFPCR) due to the rapid turnaround time and followed by chromosome 
410 analysis, either by karyotype, or more commonly, microarray, which identifies copy number variation 
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412 investigations might be reserved until answers from analysis are obtained, with the potential to avoid 
413 further costly and invasive investigations. However, there are existing challenges in bringing HTS and 
414 WGES into mainstream practice (53,54). Pre-test counselling needs to be broader, to cover all potential test 
415 outcomes, including the identification of gene variants of uncertain significance (VOUS) whilst explaining 
416 the limitations of this approach such as the variable coverage of the genes of interest in WGES. In addition, 
417 in line with international recommendations, patients and parents should be informed about the possibility of 
418 unsolicited findings of medically relevant disease variants. In NHS England, diagnostic genetic testing for 
419 DSD is included in the National Genomic Test Directory 
420 (https://www.england.nhs.uk/publication/national-genomic-test-directories/) and in both England and 
421 Scotland it is provided through a network of NHS genomic laboratory centres. Diagnostic interpretation of 
422 the genetic findings requires a very careful and methodical approach and, to deliver a high quality service, 
423 centres that provide a diagnostic genetic service for DSD should have detailed phenotypic information in 
424 addition to the genetic findings and which can be discussed at a regular meeting of a diagnostic board and 
425 which, as a minimum, consists of the clinical geneticist, the molecular geneticist, the clinical biochemist 
426 and the paediatric endocrinologist with a special interest in DSD at the diagnostic centre (54). This 
427 diagnostic board should have the capacity to review their own activities and remain up to date with 
428 continuing advances in this field.
429
430 Close involvement of the clinical genetics service can ensure that the MDT covers all aspects of genetic 
431 counselling including provision of information to the family, the mode of inheritance of the disorder and 
432 the choices or options available for dealing with this risk. Established links with the clinical genetics 
433 service are also useful when considering prenatal testing or interventions such as steroid hormone therapy 
434 in CAH or interruption of pregnancy. As the scope for non-invasive prenatal diagnosis (NIPD) using free 
435 floating foetal DNA continues to increase, the close involvement of the clinical geneticist at a very early 
436 stage in at-risk pregnancies will become even more important (55). Abnormalities of sex chromosomes are 
437 identified in approximately 1% of all pregnancies that undergo prenatal karyotype and although 40% of 
438 these pregnancies may be associated with a termination, early referral for genetic counselling seems to be 
439 associated with a lower likelihood of termination (56). 
440
441 Assessment of anatomy
442 Examination and assessment by a paediatric surgeon with experience of DSD is critically important in the 
443 affected newborn. Combining expert physical examination with radiological assessment and endoscopic 
444 visualization, when necessary, can provide information on the location and state of the gonads, the 
445 urogenital sinus and Müllerian structures. During this initial assessment, the anatomy and drainage of the 
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447
448 Ultrasonography is the first line imaging modality and should include the adrenals, kidneys, pelvis, inguinal 
449 regions and labioscrotal folds where appropriate (57). In the neonate, the uterus, ovaries and adrenals 
450 should be identifiable, but the likelihood of success is dependent on the state of the child and the expertise 
451 of the operator. It should also be borne in mind that the presence of a uterine structure does not guarantee 
452 later function and intra-abdominal testes and streak gonads are difficult to identify ultrasonography. In the 
453 prepubertal adolescent, it may be difficult to confirm the presence of a uterus by ultrasonography and 
454 repeat imaging after a 6-month course of oestrogen may be required. Although MRI seems to be used more 
455 often these days, in children, its use should be considered ancillary to ultrasound (58) and it should be 
456 reserved for cases where ultrasonography has failed to delineate the relationship of the Müllerian structures 
457 and where there are abnormalities of the urinary tract. High resolution MRI should include the pelvis & 
458 perineum with and without fat saturation and T1 in three planes where possible. MRI can identify extra-
459 abdominal ectopic testes and the presence of the spermatic cords, but may not be superior to ultrasound 
460 examination for identifying the presence and character of intra-abdominal testes or streak gonads (59). In 
461 adolescents, MRI can delineate structural anomalies such as haematocolpos or hydronephrosis, identify 
462 secretory tumours and identify the location of the intra-abdominal gonads. However, the value of this 
463 modality, as well as that of ultrasound scanning in identifying early neoplasia in retained testes remains 
464 questionable (60, 61). Apart from the above, MRI imaging of the upper abdomen in adolescents is not 
465 required unless there is an adrenal mass in which case contrast enhancement shall also be required.
466
467 Nowadays, the “genitogram” is not routinely performed for diagnostic purposes. It has been superseded by 
468 endoscopic examination of the genital tract (genitoscopy), which provides a more detailed and thorough 
469 assessment. However, a genitogram, performed in preparation for surgery allows the placing of stents in 
470 various internal structures to allow a more focused radiological examination. These investigations should 
471 provide information on the length of the urogenital sinus, the associated Müllerian structures and the 
472 relationship of the urethra and its sphincter. In 46, XX DSD, genitoscopy can assess drainage of both the 
473 bladder and Müllerian structures and provide a detailed assessment of the urogenital anatomy. In 46, XY 
474 DSD, endoscopic examination can be used to identify any Müllerian remnants that arise from the posterior 
475 urethra.
476
477 Genitoscopy can be combined with laparoscopy, but this is not necessary in all cases of DSD. Laparoscopy 
478 is a very effective method of inspecting the internal sex organs and facilitates manipulation or biopsy of 
479 intra-abdominal gonads (62,63). However, as laparoscopy can only visualize intraperitoneal structures, 
480 Müllerian remnants deep within the pelvis or closely attached to the bladder may not be seen. In 46, XY 
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482 identified and brought down to the scrotum if possible. Laparoscopy can also be used in adolescents who 
483 present with a DSD. However, MRI may be a more suitable first line investigation for defining the 
484 anatomy. 
485
486 Steroid measurement & its interpretation
487 Steroid hormone analysis is a vital component of the biochemical evaluation, but the method of analysis 
488 can have a significant impact on the result. Liquid chromatography linked with tandem mass spectrometry 
489 (LC-MS/MS) allows multiple analyte analysis from a single sample whilst maintaining analytical 
490 specificity (64) and, in cases of DSD, plasma or serum steroids should be measured by LC-MS/MS which 
491 is available increasingly widely in the UK (65). It is expected that over the next few years, further advances 
492 in the range of steroids that can be routinely measured in diagnostic laboratories in the UK will lead to 
493 greater diagnostic accuracy. For instance, LC-MS/MS based analysis of multiple steroids including 17OHP, 
494 21-deoxycortisol and 11-deoxycortisol may provide greater diagnostic precision at an earlier stage in a 
495 newborn with CAH (66).  However, there is a need for a sustained effort at ensuring that these diagnostic 
496 services contribute to external quality assessment. Close communication between the clinical and 
497 biochemistry personnel within the DSD team is vital to enable correct interpretation of laboratory results 
498 and awareness that results should be available in a timely manner. In addition to serum steroid analysis, 
499 USP analysis by gas chromatography mass spectrometry (GC-MS) can provide additional and more 
500 comprehensive qualitative and quantitative data on excretion of steroid metabolites. As gonadotrophins, 
501 androgens and precursors, fluctuate markedly over the first few months of life and may lead to a 
502 diagnostically blind window there is a place to consider an early neonatal collection as well as further 
503 samples at a later stage. A urine sample can be frozen and stored for many years and may help with a 
504 review of the diagnosis at a later stage. USP is not appropriate for suspected cases of 5α-reductase type 2 
505 deficiency until after 3 months of age as diagnostic pairs of 5β to 5α reduced metabolites are not detectable 
506 until then (67). As urine metabolites may also fluctuate during the day (68), in cases where there is a high 
507 level of suspicion, the clinician should consider a 24-hour urine collection. The number of steroid 
508 metabolites that can be measured on a USP has also increased dramatically over the past few years and 
509 whilst ratios of individual metabolites may provide greater discriminatory power (69) their utility in routine 
510 clinical practice needs further review (70).  Normally, infants, particularly boys, have significant changes in 
511 steroid and other endocrine hormone concentrations during the first 100 days of birth (64). In boys, serum 
512 testosterone and DHT may initially be high at birth but decline to less than 1 nmol/L or undetectable, 
513 respectively. Concentrations then rise from around day 30 after birth to peak at day 70 before declining to 
514 normal prepubertal concentrations (71). These normal variations may influence the interpretation of sex 
515 steroid and gonadotrophin measurements as well as the results of the hCG stimulation test. Furthermore, 
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517
518 Peptide Hormones 
519 Analysis of peptide hormones is important in investigation of suspected DSD and these hormones include 
520 the gonadotrophins, LH and FSH, anti-Müllerian hormone (AMH) and inhibin B. The absolute levels of 
521 gonadotrophins as well as the ratio of LH:FSH show sexually dimorphic patterns during the first year of 
522 life (72). In addition, they are helpful in in the assessment of primary hypogonadism as well as 
523 hypogonadotrophic hypogonadism (73). In those cases, where there is a suspiciaon of hypogonadotrophic 
524 hypogonadism, an LHRH stimulation test may need to be considered as well as investigations that exclude 
525 other pituitary hormone deficiencies. AMH is strongly expressed in Sertoli cells from the time of testicular 
526 differentiation to puberty and to a much lesser degree in granulosa cells from birth to menopause and is 
527 widely used nowadays to assess ovarian reserve (74). In the past, circulating AMH concentrations had to be 
528 interpreted with caution due to differences in the way immunoassays were standardised but nowadays 
529 commonly used assays show very low inter-assay variance (75). In boys, AMH is detectable at birth at a 
530 much higher circulating concentration in boys than in girls and these concentrations rise over infancy 
531 before gradually declining at puberty. Therefore, up to date, age, sex and method-related reference ranges 
532 are necessary for interpretation (73). In male neonates, levels that are close to the lower end of the normal 
533 range should be repeated later in infancy as they should rise further in boys with normal testes. The 
534 measurement of AMH is a powerful tool to assess Sertoli cell activity in children with suspected DSD and 
535 may also have a diagnostic utility in conditions associated with androgen deficiency or insensitivity where 
536 AMH may be raised and in hypogonadotrophic hypogonadism where AMH may be low (76). The 
537 discriminant value of AMH in cases of bilateral anorchia is so high that an undetectable AMH in such a 
538 case may avoid the need for invasive surgical exploration (77). Inhibin B is a dimeric disulphide-linked 
539 glycoprotein consisting of two subunits (i.e. α and β) and like AMH, it is part of the TGFβ protein family. 
540 The main role of inhibin is the down-regulation of FSH synthesis and like AMH it can act as a marker of 
541 functioning testicular and ovarian tissue (78). However, unlike AMH, the peptide hormone assays for 
542 inhibin B are not currently included in any external quality control exercise in the UK (73).  The utility of 
543 measuring circulating inhibin B maybe greatest from late childhood when unlike AMH which falls to low 
544 levels during adolescence, inhibin B levels rise higher (76, 78). Recently, INSL3 has been reported as a 
545 marker of Leydig cell activity (79) and its utility in the evaluation of conditions associated with DSD needs 
546 further exploration.
547
548 The human chorionic gonadotrophin (hCG) stimulation test
549 Stimulation with hCG allows the identification of functioning Leydig cells as well as biosynthetic defects 
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551 as outlined in Fig.3 and it should only be performed at a later stage in the diagnostic pathway under the 
552 direction of the regional DSD centre (54). Generally, in routine cases of XY DSD, serum AMH has a high 
553 predictive value for a post-hCG testosterone (80). Most protocols for hCG stimulation in the UK use 
554 intramuscular hCG 1000-1500units on 3 consecutive days (81) and this can be followed by further hCG 
555 stimulation with 1500units on two days a week for the following two weeks for a prolonged period of hCG 
556 stimulation (82). The three week hCG stimulation test may be more appropriate in those cases where there 
557 is a high suspicion that a functioning gonad may not be present such as in bilateral cryptorchidism or where 
558 there is a high suspicion of hypogonadotrophic hypogonadism where the Leydig cells may require more 
559 prolonged stimulation.  In young infants and adolescents, 3 days of hCG stimulation may be sufficient and 
560 in the very young infant with an intrinsically active gonadal axis, an hCG stimulation test may not be 
561 necessary if serial blood samples show raised serum testosterone concentrations. A testosterone response to 
562 hCG may be labelled as normal if absolute testosterone concentrations reach a level that is above the upper 
563 limit of the normal prepubertal range or rise by more than twice the baseline value (83). Other androgens 
564 that should also be measured include androstenedione and dihydrotestosterone and with the use of LC-
565 MS/MS, the sample volumes have become lower. For these two metabolites, the post-hCG, day 4 sample is 
566 more important than the pre-hCG sample on day 1. If a prolonged hCG stimulation test is performed, the 
567 day 22 sample that is collected at the end for testosterone measurement should be stored and can be used to 
568 measure DHT or androstenedione if a sufficient sample was not available on day 4. There is no evidence 
569 that a urine steroid profile or a serum AMH checked after hCG stimulation has any added diagnostic value. 
570 There is less experience as well as a lower demand for a corresponding test to assess ovarian tissue or 
571 reserve in DSD. Whilst reports of ovarian hormones following stimulation with FSH need further 
572 exploration none of the current tests of ovarian reserve are reliable predictors of reduced ovarian function 
573 (84). In the presence of a poor testosterone response following hCG stimulation, assessment of adrenal 
574 function by a standard short synacthen stimulation test should be considered. There is currently insufficient 
575 evidence to recommend that everybody with XY DSD should have a ACTH stimulation test but clinicians 
576 should be aware of the clear association between some forms of DSD and primary adrenal insufficiency 
577 and should consider thorough assessment of adrenal function in those diagnoses where an association has 
578 already been described (85) and in those with any clinical suspicion of adrenal insufficiency, especially 
579 those with low steroid precursors on USP.
580
581 XX DSD 
582 46,XX DSD can be classified into disorders of ovarian development, conditions with androgen excess and 
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585 21-hydroxylase deficiency CAH with androgen excess is the commonest cause of 46, XX DSD with 
586 atypical genitalia in the neonatal period or early infancy and is characterised by androgen excess and a 
587 variable alteration in glucocorticoid and mineralocorticoid function and a specific profile of steroid 
588 hormones (86, 87). This profile can identify the enzyme defects including deficiency of 21-hydroxylase 
589 (90-95% of cases), 11β-hydroxylase (4-8% of cases), 3β-hydroxysteroid dehydrogenase type 2 (rare) and 
590 P450 oxidoreductase (unknown prevalence). P450 oxidoreductase deficiency (PORD) biochemically 
591 manifests as apparent combined CYP17A1 and CYP21A2 deficiency, sometimes also resembling 
592 CYP19A1 (aromatase) deficiency. Unlike other forms of CAH, PORD is characterised by increased 
593 androgen concentrations only during the prenatal and early neonatal period, but rapidly develop sex 
594 hormone deficiency. Further details of these enzyme defects as well as others that can cause 46, XX DSD 
595 are outlined in Table III. 
596
597 46, XX DSD also includes disorders of gonadal development including 46, XX ovotesticular DSD and 46, 
598 XX testicular DSD. 46, XX ovotesticular DSD commonly presents at birth with atypical genitalia and 
599 progressive virilisation during puberty. In contrast, individuals with 46, XX testicular DSD usually have a 
600 male phenotype and absent Müllerian structures and are often diagnosed after karyotype analysis during 
601 work-up for infertility (88). In 46, XX testicular DSD, about 80-90% of patients will have Y chromosomal 
602 material including a translocated SRY gene, which is only rarely detected in 46, XX ovotesticular DSD. In 
603 other cases of 46, XX testicular DSD, duplications involving regulatory genes, SOX9 and SOX3 have been 
604 described.  Gene variants in NR5A1 and NR2F2 have also been reported in 46, XX testicular and 
605 ovotesticular DSD with the NR2F2 variants being associated with cardiac defects as well as other features 
606 (89). Rarely, RSPO1 and WNT4, and more recently WT1 variants have also been described (89, 90). In 
607 those with a suspicion of 46, XX ovotesticular DSD, functional testing will require detection of testicular 
608 and ovarian tissue by a combination of biochemical testing, imaging and surgical exploration. 
609
610 Disorders of Müllerian development are another group of 46, XX DSD and in these cases ovarian function 
611 is usually normal but often associated with cloacal anomalies and other characteristic malformations. Novel 
612 and recurrent copy number variations have been reported to be associated with a third of Mayer-
613 Rokitanksy-Küster-Hauser (MRKH) Syndrome and other Müllerian abnormalities (91, 92). Although most 
614 cases of Müllerian development disorders are not associated with androgen excess, the presence of the 
615 latter, particularly in the adolescent, should alert the clinician to a possible abnormality of the WNT4 gene. 
616 Variants in a wide range of genes have now been described to be associated with uterine abnormalities and 
617 often these conditions are associated with multiple other anomalies (93). 
618
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620 The differential diagnosis of 46, XY DSD associated with low testosterone and low precursors includes: 
621 high defects in steroid synthesis (steroidogenic acute regulatory (StAR) protein, P450 side chain cleavage 
622 (P450scc) enzyme/CYP11A1, sometimes Smith-Lemli-Optiz/DHCR7); LH receptor defects (LHCGR); and 
623 partial and complete forms of gonadal dysgenesis (Table IV).
624
625 Of note, complete or partial combined 17α-hydroxylase/17,20-lyase deficiency (CYP17A1) may also 
626 present with “low testosterone and low precursors” if DHEAS and androstenedione are the only 
627 intermediates measured. The actual diagnosis can be reached by assessment of adrenal function by 
628 measuring ACTH, ACTH-stimulated cortisol, plasma renin activity (PRA), 11-deoxycorticosterone (DOC), 
629 corticosterone, aldosterone, measurement of Δ5 (pregnenolone, 17OHPreg) and Δ4 (progesterone, 17OHP) 
630 precursors or urine steroid analysis. Isolated 17,20-lyase deficiency, cytochrome b5 deficiency and PORD 
631 might also be diagnosed by this approach. Proximal blocks (StAR, P450scc) in the pathway affect 
632 steroidogenesis in the adrenal gland as well as the developing gonad. 
633
634 LH receptor defects (“Leydig cell hypoplasia”) typically result in elevated basal LH, hyperresponsive LH 
635 to GnRH stimulation, low precursors and testosterone, and impaired androgen response to hCG stimulation. 
636 No Müllerian structures will be present and adrenal function is normal. A spectrum of phenotypes has been 
637 reported including atypical genitalia and micropenis. In some cases, basal LH may not be elevated at times 
638 when the HPG axis is quiescent (6 months to late childhood). 
639
640 In complete gonadal dysgenesis (“Swyer syndrome”), affected people will usually have a female phenotype 
641 with intra-abdominal dysgenetic streak gonads and a risk of tumour development. In some situations, 
642 ovotestes or even undifferentiated gonadal tissue may be found (94). Müllerian structures are usually 
643 present due to impaired AMH secretion in early foetal life. Androgens and their precursors will be low, LH 
644 elevated, depending on age, and a poor or absent testosterone response to hCG stimulation is seen. AMH 
645 concentrations will be low or undetectable and adrenal function is usually normal unless the underlying 
646 defect is in steroidogenic factor-1 (NR5A1) or related adrenal or gonadal factors.
647
648 Partial gonadal (testicular) dysgenesis can present with a spectrum of phenotypes ranging from 
649 clitoromegaly, to atypical genitalia or severe hypospadias. Müllerian structures may or may not be present 
650 and testes of variable size and architecture are present along the path of descent. The biochemical profile is 
651 similar to complete gonadal dysgenesis, but generally less severe. If mild degrees of clitoromegaly in 
652 infancy are overlooked, a 46, XY child with partial gonadal dysgenesis may first present at puberty with 
653 progressive androgenisation. Genetic analysis and associated features may be useful in defining the 
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655 risk of tumour development which may be related to the extent of androgenisation of the external genitalia 
656 in the XY child (95).
657
658 XY DSD with low testosterone and high steroid precursors
659 46, XY DSD with low testosterone and increased precursors can be caused by several variants of CAH, 
660 namely by 17α-hydroxylase (CYP17A1) deficiency, PORD and 3β-hydroxysteroid dehydrogenase type 2 
661 (HSD3B2) deficiency, caused by inactivating gene variants in the corresponding genes CYP17A1, POR and 
662 HSD3B2, respectively. In addition, 46, XY DSD with low testosterone and increased precursors can 
663 typically be found in individuals affected by 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3) 
664 deficiency, caused by HSD17B3 variants (Table IV). 
665
666 Deficiency of CYP17A1 leads to CAH in about 1% of cases of 46, XY DSD. Characteristically, affected 
667 individuals present with external female genitalia and low DHEA, androstenedione and testosterone. There 
668 is an increase in mineralocorticoid synthesis and although there may be cortisol deficiency this is rarely 
669 manifested, as corticosterone can also bind and activate the glucocorticoid receptor. In PORD, sex steroids 
670 are characteristically low, sometimes low normal, while pregnenolone and progesterone and their 
671 metabolites accumulate, as expression of the combined block of CYP21A2 and CYP17A1 activities. 
672 Though there is often a relative preponderance of mineralocorticoid over glucocorticoid metabolites in 
673 affected cases, hypertension only manifests in adolescence or later. Although baseline glucocorticoid 
674 secretion is usually sufficient, in the majority of cases, the stress response to ACTH is significantly 
675 impaired, requiring at least stress dose hydrocortisone cover or permanent glucocorticoid replacement. 3β-
676 HSD2 (also termed Δ4-Δ5 isomerase) deficiency invariably leads to glucocorticoid deficiency and as well 
677 as a variable degree of mineralocorticoid deficiency and its characteristic features are outlined in Table IV. 
678 17β-HSD3 deficiency is responsible for the conversion of androstenedione to testosterone in the gonad and 
679 has no effect on adrenal steroidogenesis. Plasma steroids characteristically show increased androstenedione 
680 levels while testosterone levels are concurrently low, particularly after hCG stimulation. However, a low 
681 testosterone to androstenedione ratio may also occur in cases of gonadal dysgenesis and the reliability of a 
682 low ratio in identifying 17β-HSD3 deficiency is unclear. In urine, the typical finding is an increase in the 
683 androgen (and androstenedione) metabolites, androsterone and etiocholanolone, but this may only become 
684 apparent after puberty. 
685
686 XY DSD with normal testosterone, normal precursors and low DHT
687 The type 2 isoenzyme of 5α-reductase type 2 (SRD5A2) is highly expressed in androgen sensitive tissues 
688 and converts testosterone to the more potent androgen, dihydrotestosterone (DHT) required for the 
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690 SRD5A2 deficiency can range from a completely female phenotype to a range of hypospadias severity or, 
691 rarely, isolated micropenis. A positive family history is often present in this autosomal recessive condition. 
692 In serum, the testosterone:DHT ratio following hCG stimulation often exceeds 30:1 but there are several 
693 reports of cases with a lower ratio (96).  In infants over 3 to 6 months, the defect should be easily 
694 identifiable simply on a urine sample which shows a decreased ratio for 5α:5β-reduced C21 and C19 steroids 
695 thus and can be reached in a child who had early gonadectomy. Early diagnosis of this condition is 
696 important for sex assignment and definitive diagnosis in a highly suspicious case may require access to a 
697 diagnostic genetics service with a quick turnaround time. With the wide availability of rapid genetic testing, 
698 the diagnosis of SRD5A2 deficiency is an example of a condition where molecular genetics is superseding 
699 detailed biochemistry as the preferred diagnostic tool (6).  In the infant raised as a boy, application of 
700 topical DHT may be a method of assessing the potential of the genitalia to virilise over the longer term. 
701 With the discovery of the alternative “back door” pathway to DHT synthesis, there is a possibility that 
702 defects in the aldoketo reductase pathway may also lead to XY DSD (97) but the clinical significance of 
703 this defect in the presence of normal 5α-reductase remains debatable (98).
704
705 XY DSD with normal testosterone, normal precursors and normal DHT
706 A defect in androgen signalling is most likely due to dysfunction of the androgen receptor protein (AR) and 
707 gene variants resulting in a complete lack of function of the AR cause Complete Androgen Insensitivity 
708 Syndrome (CAIS) (99). This presents in the newborn infant as a discordance between a female phenotype 
709 and a prenatal karyotype of 46, XY, a postnatal check because of a positive family history, or as inguinal or 
710 labial swellings in a girl. CAIS usually presents in adolescence as primary amenorrhoea with normal breast 
711 development and absent uterus. The presence of pubic hair is often reported in CAIS and should not be 
712 used to exclude the diagnosis. AR gene variants that result in some residual AR function and varying 
713 degrees of androgenisation cause Partial Androgen Insensitivity Syndrome (PAIS). Although children with 
714 AIS typically have normal testosterone and DHT response to hCG stimulation and a normal urinary steroid 
715 profile, some demonstrate a poor response to hCG stimulation (81). The serum AMH concentration is 
716 normal or may even be elevated. LH levels are increased in the face of normal or elevated serum 
717 testosterone, reflecting a state of androgen resistance. A family history of X-linked inheritance is 
718 informative although one-third of cases are the result of spontaneous new gene variants.
719
720 A functional assessment of androgen sensitivity may include assessing the clinical effect of a short course 
721 of testosterone or dihydrotestosterone applied on the phallus or by the effect of systemic testosterone 
722 following hCG stimulation. However, there is no consensus on the choice of androgen, dosage, method of 
723 administration, timing and duration of treatment as well as the definition of an optimal response in the 
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725 responsive circulating proteins such as SHBG following androgen exposure but this is rarely performed in 
726 clinical practice as the response can be very variable. There may be other methods of assessing tissue 
727 responsiveness to androgens including the measurement of androgen responsive proteins in genital skin 
728 fibroblasts (100) or the assessment of the androgen responsive transcriptome (101) but their clinical utility 
729 requires further exploration. AR analysis may reveal a causative gene variant in over 90% of cases with a 
730 CAIS phenotype but given that only 20% of cases with a PAIS phenotype have a variant in the coding region 
731 of AR (102), there is a need to improve the diagnosis of this condition especially as it has been reported that 
732 the gene variants in AR may exist beyond the coding sequence (100). A number of newborns with XY DSD 
733 are loosely labelled as ‘PAIS’ when no conclusive biochemical or genetic abnormalities are identified in 
734 gonadal function, androgen synthesis or androgen action. However, the term PAIS should only be used in 
735 the context of a molecular confirmation of a likely causative AR variant as there is great prognostic value in 
736 having a genetically confirmed diagnosis of PAIS (103). The majority of infants with XY DSD 
737 encountered in a DSD clinic and who are systematically investigated do not have an endocrine disorder of 
738 androgen synthesis and do not have a variant in AR (37). Whilst in some of them, there may be other 
739 phenotypic clues, such as in the case of Persistent Mullerian Duct Syndrome (104), in others, the aetiology 
740 may only become clear with further clinical follow-up. The use of HTS in such cases has also started to 
741 identify variants in a wide range of genes that may have a role to play in genital tubercle development or 
742 testis migration (105).
743
744 Conclusion
745 Whilst the overarching rationale for investigating a newborn or an adolescent with a suspected DSD is to 
746 minimise the level of uncertainty, more specifically and commonly, it will include the need to work with 
747 the family to provide information and discuss whether the child is brought up as a boy or a girl, anticipate 
748 early medical problems, explain the aetiology to the young person or the parents of an affected newborn, 
749 support them psychologically in assimilating this knowledge and, finally, to develop a management plan 
750 that leads to optimal long-term outcome. A rational, stepwise and empathic approach that relies on the 
751 skills and knowledge of the experts within the MDT is essential for achieving these goals. The ultimate 
752 ambition of preserving a physically and psychologically well adult must be held in mind from the earliest 
753 care of the newborn, child or adolescent with a suspected DSD.
754
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Neonatologist or General 
Paediatrician
- Initial explanation
- Management of the unwell child
- Initiation of first line investigations
- Seek advice from paediatric subspecialist (endocrine or surgical) with an interest in DSD
Paediatric Endocrinologist  - Detailed explanation over multiple visits
- Management of the unwell child
- Interpreting first line investigations and planning second line investigations
- Organise timely and appropriate involvement of other members of MDT
- Act as the link between the parents and MDT
- Initiate and monitor long-term medical therapy such as steroid or sex steroid therapy
Paediatric Radiologist -  Interpret and often perform ultrasound scans in the newborn
-  Judge the reliability of ultrasound scans in the newborn esp when the results  
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Paediatric Urologist -  Assessment of external anatomy
-  Explanation of the anatomy and results of imaging
-  Explanation of pros and cons of surgery
-  Develop a plan for complex imaging (other than pelvic ultrasound) and further  
    assessment of the anatomy 
-  Perform procedures such as laparoscopy, biopsy, reconstructive surgery and 
   gonadectomy
-  Organise timely and appropriate involvement of other members of MDT
Paediatric Specialist Nurse -  Provide general support to the patient and parents in addition to that provided by 
   other members of the MDT
-  Arrange specialist investigations
-  Liaise with the rest of the DSD team, including the clinical psychologist
Clinical Psychologist -  Provide specialist support to parents soon after birth 
-  Provide support to the growing up child and the parents
-  Develop an individualized plan for each family
-  Guide the MDT on timing and tempo of explanation of the condition to the older  
    child and adolescent
Clinical Endocrine 
Biochemist*
-  Facilitate timely analysis of samples 
-  Provide specialist support and interpretation of results
-  Guide subsequent biochemical tests
-  Facilitate storage of samples for analysis at a later stage   
Clinical Geneticist -  Facilitate timely analysis of chromosome analysis
-  Closer involvement in the child with dysmorphic features
-  Oversee the process of genetic analysis
-  Facilitate storage of samples for analysis at a later stage   
-  Genetic counselling 
Gynaecologist -  Availability at an early stage to discuss future outcome and map long-term care pathway 
in the affected girl
-  Discuss issues related to sexual function, reproductive function and surgery
-  Assess the understanding & review the diagnosis 
-  Assess the need for psychology support in the adolescent girl
-  Initiate and monitor long-term sex steroid therapy 
-  Perform examination, investigative and therapeutic procedures in the adolescent girl
- Oversee vaginal dilator training with specialist nurse
Adult Endocrinologist -  Investigate and manage the adolescent presenting for the first time after the age 
   of 16 yrs
- Liaise with other members of the MDT
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- Initiate and monitor long-term medical therapy such as steroid or sex steroid therapy 
- Act as the transition link for adolescents under paediatric care
Service Coordinator - Oversees the coordination of a complex clinical service
- Responsible for data management
- Oversees activities related to audit and benchmarking of services
- Oversees public and professional engagement of the service
1122













ARX XLD XY + lissencephaly, epilepsy, learning difficulty
ATRX XLD:del XY learning difficulty, α-thalassemia
BMP15 XLD XX +
CBX2 AR XY +
DAX1 XL:dup XY +
DHH AR/AD XY + minifascicular neuropathy
DHX37 AD XY +
DMRT1 AD:del XY + learning difficulty
EMX2 AD:del XY + learning difficulty, renal agenesis
ESR2 AR/AD XY +
FGF9 AD XX +
FGFR2 AD XY + craniosynostosis
FOXL2 AD XX + blepharophimosis, epicanthus inversus and ptosis
GATA4 AD XY + congenital heart disease
HHAT AR XY + short stature, generalised chondrodysplasia, 
muscle hypertrophy, myopia, intellectual 
deficiency
MAP3K1 AD XY +
NR2F2 AD + + congenital heart defects, congenital 
diaphragmatic hernia, blepharon-phimosis-
ptosis-epicanthus inversus syndrome
NR5A1 AD XX + + +
NR5A1 AR/AD XY + rarely primary adrenal insufficiency
NUP107 AR XX +
RSPO1 AR XX + + palmoplantar hyperkeratosis, squamous cell 
carcinoma of skin
SOX3 XL:dup XX + +
SOX8 AD XY + skeletal anomalies, learning difficulty
SOX9 AD:dup XX + +
SOX9 AD XY + campomelic dysplasia
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peripheral neuropathy
SRY T XX + +
SRY Del XY +
STARD8 XL XY +
TSPYL1 AR XY + abnormal brain stem development, sudden infant 
death
WNT4 AR/AD XX + + sex reversal dysgenesis of kidneys, adrenals and 
lung, lethal when biallelic
WNT4 AD:dup XY + + may also only have ovarian tissue
WT1 AD XX +
WT1 variable XY + deletion – WAGR syndrome, inactivation – 
Denys Drash Syndrome, splicing – Frasier 
Syndrome
WWOX AD;del XY + epilepsy
ZFPM2 AD XY + + congenital heart disease
ZNRF3 AD XY +
1127
1128 Table II A selection of genes associated with disorders of gonadal development in XX and XY DSD. It is 
1129 beyond the scope of this table to include all the congenital conditions and syndromes that are associated 
1130 with atypical genitalia. AD: autosomal dominant;  AR: autosomal recessive;  del: deletion; dup; 
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Gonads Typical signs and symptoms Hormone profile
21-hydroxylase def Autosomal Recessive, 
CYP21A2
Wide range of 
atypical 
genitalia
Absent Normal Ovary Severe adrenal insufficiency in infancy 
 salt loss; moderate to severe 
androgenisation at birth
Decreased cortisol and/ or mineralocorticoids.
Increased 17-hydroxyprogesterone, 21-
deoxycortisol, androstenedione, testosterone, 
and/ or plasma renin (activity)
11β-hydroxylase def Autosomal Recessive, 
CYP11B1
Wide range of 
atypical 
genitalia
Absent Normal Ovary Adrenal insufficiency in infancy; 
moderate to severe androgenisation at 
birth; arterial hypertension often 
developing at different ages
Decreased cortisol, corticosterone, aldosterone, 












can also be 
normal
Absent Normal Ovary Severe adrenal insufficiency in infancy 
 salt loss, androgenisation during 
childhood and puberty, premature 
pubarche 
Increased concentrations of Δ5 C21- & C19- 
steroids, 17 hydroxypregnenolone and DHEA 
suppressible by dexamethasone
P450 oxidoreductase def Autosomal Recessive, 
POR 






Absent Normal Ovary Variable androgenisation at birth and 
puberty, glucocorticoid deficiency, 
features of skeletal malformations.
Maternal androgenisation during 
pregnancy onset second trimester 
possible
Combined P450c17 & P450c21 insuff, normal 
or low cortisol with poor response to ACTH 
stim, elevated 17-hydroxyprogesterone, 
testosterone, progesterone and corticosterone; 
low oestradiol
P450 aromatase def Autosomal Recessive, 
CYP19A1
Wide range of 
atypical 
genitalia
Absent Normal Ovary Delayed bone age, development of 
ovarian cysts during infancy, childhood 
and puberty. Maternal androgenisation 
during pregnancy
High androgens in cord blood, androgens may 







Absent Normal Ovary Typically presents in young women 
with signs of androgen excess and 
High/normal ACTH and high serum and 
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fatigue with or without 
mineralocorticoid excess, hypertension 
and bilateral adrenal hyperplasia.
dexamethasone
Table III: Characteristics of 46, XX DSD associated with androgen excess 




Gonads Typical features Hormone profile
LH deficiency or 
bioinactivity










Normal Absent Testes May be associated with other features 
of hypopituitarism or syndromes 
associated with CHH. May present in 
early infancy or adolescence with 
pubertal delay.
Poor response to LHRH stimulation test, low 
AMH, variable testosterone response to hCG 
stimulation test.
Leydig cell hypoplasia Autosomal Recessive, 
LH/HCGR 




Hypoplastic Absent Testes Underandrogenisation with variable 
failure of sex hormone production at 
puberty
Low T & DHT, elevated LH & FSH, 
exaggerated LH response to LHRH, poor T & 
DHT response to hCG stimulation










This article is protected by copyright. All rights reserved










Absent Testes Severe adrenal insufficiency in infancy 
with salt loss, failure of pubertal 
development, rare cases associated with 
isolated glucocorticoid deficiency
Usually deficient of glucocorticoids, 
mineralocorticoids & sex steroids
P450 side-chain 








Absent Testes Severe adrenal insufficiency in infancy 
with salt loss ranging to milder adrenal 
insufficiency with onset in childhood
Usually deficient of glucocorticoids, 












Normal Absent Testes Severe adrenal insufficiency in infancy 
 salt loss, poor androgenisation at 
puberty with gynaecomastia
Increased concentrations of Δ5 C21- & C19- 











Absent Testes Absent or poor androgenisation at 
puberty, gynaecomastia, hypertension
Decreased T, increased LH & FSH, low 
cortisol, increased plasma deoxycorticosterone, 
corticosterone & progesterone, decreased 






affecting key redox 
domains, alternatively 
caused by cytochrome 
b5 variants (CYB5)




Absent Testes Absent or poor androgenisation at 
puberty, gynaecomastia
Decreased T, DHEA, androstenedione & 
oestradiol, abnormal increase in plasma 17-
hydroxyprogesterone & 17-
hydroxypregnenolone, increased LH & FSH, 
increased ratio of C21-deoxysteroids to C19-










Absent Testes Variable androgenisation at birth and 
puberty, glucocorticoid deficiency, 
features of skeletal malformations 
Combined P450c17 & P450c21 insuff, normal 
or low cortisol with poor response to ACTH 
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(Antley Bixler Syndrome)
Maternal androgenisation during 










Absent Testes Associated with clinical and 
biochemical features of 
methemoglobinemia. Low 
methemoglobin reductase activity and 
low red cell cytochrome b5.
Low androgen metabolite excretion with 
increased excretion of pregnenetriol and 
normal mineralocorticoid and glucocorticoid 
metabolite excretion. Ratio of corticosterone 
over cortisol metabolites normal and elevated 
ratio of 17-alpha-hydroxyprogesterone over 
androgen metabolites 
17β-hydroxysteroid 








Present Absent Testes Androgenisation at puberty, 
gynaecomastia variable
Increased plasma estrone, decreased ratio of 
testosterone/ androstenedione and oestradiol 











Absent Testes Decreased facial and body hair, no 
temporal hair recession, prostate not 
palpable. Will androgenise in puberty
Decreased ratio of 5α/5β C21- & C19- steroids in 
urine, increased T/DHT ratio before & after 
hCG stim, modest increase in LH, decreased 











Absent Testes Similar features to 5α-reductase-2 
deficiency but not expected to  
androgenise in puberty.
DHT deficiency and apparent 17,20-lyase 










Absent Testes Scant or absent pubic & axillary hair, 
breast development & female body 
habitus at puberty, primary amenorrhea
Increased LH & T, increased oestradiol, FSH 
levels normal or slightly increased, resistance 
to androgenic & metabolic effects of T (may 





Wide range of 
atypical genitalia 
including normal 
Often normal Absent Testes Decreased to normal axillary & pubic 
hair, facial & body hair, gynaecomastia 
common at puberty
Increased LH & T, increased oestradiol, FSH 
levels may be normal or slightly increased, 
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Legend To Figures
Fig.1 Approach to investigating adolescent girls with primary amenorrhoea.
Fig.2 An integrated pathway for genomic and phenotypic evaluation of DSD.  VOUS – 
variant of unclear significance. A multidisciplinary diagnostic team that has detailed 
knowledge of the DSD field as well as the diagnostic tools plays a central role in the 
diagnostic process.
Fig.3 Interpretation of the results of the hCG stimulation test when investigating XY DSD 
and pointers for consideration of prolonged hCG stimulation and ACTH stimulation. 
*A prolonged hCG stimulation test should be considered in those cases where there is 
a poor testosterone response to a standard hCG stimulation test or where a poor 
response is anticipated. **A synacthen stimulation test should be considered in those 
cases who show a poor testosterone response to hCG stimulation or if there is a clinical 
or biochemical suspicion of adrenal insufficiency. 17α-OH - 17α hydroxylase, 
17bHSD3 - 17β-hydroxysteroid dehydrogenase type 3, 3HSD2 def - 3β-
hydroxysteroid dehydrogenase II, AIS – androgen insensitivity syndrome, AKR – 
aldoketoreductase, CAH – congenital adrenal hyperplasia, LCH – Leydig Cell 















Ovarian Insufficiency              
Turner Syndrome   
46,XY Disorder of gonadal development 




Disorder of Müllerian development 
46,XY Disorder of androgen synthesis 
46,XY Disorder of androgen action 
 
 





















• Single gene analysis (only if monogenic 
condition clearly  suspected) 
• Microarray (if not done already, 
particularly if associated malformations) 
• High Throughput Sequencing 
 
Initial evaluation  
•Clinical phenotyping – history and examination  
•Chromosome analysis (QF-PCR then Karyotype/Microarray) 
•Consent for DNA storage and genomic testing 
DSD Multidisciplinary Team Meeting  
• Clinical endocrinology  
• Steroid & peptide biochemistry  
• Clinical genetics  
• Molecular genetics 
46,XX DSD or 46,XY DSD 
Liaise and discuss results 
with clinical geneticist in 
DSD team 
 
Sex chromosome DSD or 
chromosome variation 





VOUS or No causal genetic 
variants identified 
 
Consider WES/WGS, especially if: 
• Associated malformations  
• Endocrine abnormalities   
• Positive family history 
• Parental consanguinity 
Clinical Genetics  
• Genetic counselling 
• Plan any further tests 
• Cascade genetic 












Low T &  
Low Precursors 




High / Normal / Low T 
Normal DHT 
Normal / High AMH 
Poor/Normal functional response to T 














Non-specific XY DSD 
Standard HCG stimulation 
ACTH stimulated Cortisol Response** 
Prolonged HCG 
stimulation* 
Low T &  
Low Precursors 
Normal Low Normal Low 
17βHSD3 def 
17,20-lyase def 
Cytochrome B5 def 
  
Urinary 5β:5α 
Normal High 
AKR def 
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